The manufacturers of the blood thinner drug Xarelto won another case filed against them over the drug's alleged excessive bleeding effect. Philadelphia Court of Common Pleas announced the verdict after a four-week trial against Bayer and Johnson & Johnson.
The case involves the allegations by a 63-year-old New Jersey resident that he suffered “gastrointestinal bleeding" under Xarelto treatment for his pulmonary embolism. The plaintiff had been prescribed the drug, which he continued to consume from November 2014 to December 2015. In his 2016 complaint, he alleges inadequate warnings regarding the health risks of the drug required him to be hospitalized for four days due to excessive bleeding. The jury ruled in favor of Bayer and J&J over claims that they failed to provide sufficient health risk warning, awarding them another victory in the massive Xarelto litigation.
Xarelto multidistrict litigation (MDL No.2592; In Re: Xarelto (Rivaroxaban) Products Liability Litigation) has more than 22,250 lawsuits claiming uncontrolled internal bleeding as a serious side-effect. The MDL is overlooked by Judge Fallon in the Eastern District of Louisiana.
